Atagabalin

Atagabalin is essentially Pfizer's attempt to build a cleaner gabapentin; a rigid dimethyl-cyclopentane skeleton locked onto the same alpha-2-delta calcium-channel target that makes pregabalin and gabapentin work. The appeal of the concept is that it hits the excitatory side of the ledger; it quiets glutamate release from over-firing neurons instead of flooding a GABA-A receptor the way a Z-drug does, and in the sleep studies it actually pushed slow-wave (deep) sleep up rather than just knocking people out.

It was rapidly absorbed and generally well tolerated in the early work; somnolence, dizziness and headache were the usual suspects, pretty much the standard gabapentinoid feel. Honest bottom line though; this one never crossed the finish line. Pfizer shelved it after Phase II, so it stays a research compound with no approval and no track record for chronic use. It is best filed as a neat mechanistic footnote for people who follow a2d pharmacology, not something to go source; pregabalin or gabapentin cover the same ground with real human data behind them.

Atagabalin is an investigational compound that never advanced past Phase II and is not approved or marketed anywhere; long-term safety in humans is unknown. In clinical studies the most common adverse events were somnolence, dizziness and headache, mirroring the gabapentinoid class. It is cleared renally, and exposure (AUC) increased by roughly 56, 117 and 436 percent in mild, moderate and severe renal impairment respectively, so dose adjustment would be required in reduced kidney function. As a sedating a2d ligand it would be expected to add to CNS depression when combined with alcohol or other depressants. It is not a scheduled or recreational drug, but it is not risk-free and should be treated as a research chemical.